Interestingly, statins increased the levels of PCSK9 in both, T2DM and non-DM patients and, this increment of the PCSK9 levels after the statin treatment in the T2DM group was associated with a reduction of the total levels of EPCs (CD45− CD34+) and eEPCs (CD45−CD34+CD146) [207]. This evidence concerns the gene MCAM and type 2 diabetes mellitus.